Insmed 'hopeful' over inhaled amikacin but share price continues nose dive
This article was originally published in Scrip
Executive Summary
Insmed said it is hopeful that it can resume the Phase III trial of its lead candidate Arikace (liposomal amikacin for inhalation) during the fourth quarter of the year, following a US FDA decision to place a clinical hold on the programme at the start of August. The agency based its decision on an initial review of the interim results of a long-term rat inhalation carcinogenicity study with Arikace, recently reported to the agency by Insmed.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.